Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
Patients in the Australian Idiopathic Pulmonary Fibrosis Registry who take anti-fibrotic therapies tend to live longer than those who do not, according to an analysis of the records. Another ... Read more
Inhaled nitric oxide (iNO) treatment with the investigational medical device INOpulse system in patients with pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) has shown promising results in a Phase 2 ... Read more
Genentech’s Esbriet (pirfenidone), approved by the U.S. Food and Drug Administration (FDA) in 2014 to treat idiopathic pulmonary fibrosis (IPF), prolongs survival in patients and is generally safe, concludes a review, ... Read more
A ground-breaking experiment using mesenchymal stem cells (MSCs) injected into mice models of chronic obstructive pulmonary disease (COPD) and cystic fibrosis showed that MSC therapy might be a promising approach ... Read more
“Mini lungs” created from the tissue of idiopathic pulmonary fibrosis (IPF) patients could be used to predict which of two medications would effectively treat them, according to a new study. The ... Read more
While the Affordable Care Act (ACA) improved healthcare coverage for millions of Americans with chronic illnesses, many remained without coverage and faced barriers to getting regular medical care. This ... Read more
A Phase 3 trial assessing Actelion‘s Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome did not meet its primary objective of a change in ... Read more